PharmaEssentia Reports Preclinical Data on Two Solid-Tumor Programs
PharmaEssentia reported preclinical data at SITC on PEC2001, a dual LILRB1/2 antagonist, and PEC3001, a PD-1-targeted IL-2 immunocytokine. The data support advancement toward IND-enabling and first-in-human studies.